2024-10-26 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis:

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a wide range of medications, including Humira, a top-selling drug for autoimmune diseases.

**1. Performance vs. S&P 500:**

* **Cumulative Return:** ABBV: 146.5%, VOO (S&P 500): 135.48%
* **Outperformance:** ABBV has outperformed the S&P 500 by 11.02%.
* **Relative Outperformance:** This outperformance places ABBV at the 52.99th percentile of its historical performance range relative to the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $189.65 (Last-market: $187.77)
* **5-Day Moving Average:** $187.9
* **20-Day Moving Average:** $192.57
* **60-Day Moving Average:** $193.22
* **Analysis:** ABBV's stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 37.57: The RSI indicates that ABBV is currently in oversold territory, suggesting potential for a rebound.
* **PPO:** -0.33: The PPO indicates a bearish trend, aligning with the recent downward price movement.
* **Delta_Previous_Relative_Divergence:** -4.46: Indicates a recent decline in the relative strength of ABBV compared to the S&P 500.
* **Expected Return:** 3.06%: This indicates a potential for above-average returns over the long term, compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

**Analysis:** ABBV has consistently exceeded earnings expectations in the last few quarters. The most recent earnings report, released on 2024-07-25, saw ABBV exceeding expectations by 3.1%. This strong performance indicates continued momentum and positive outlook for the company.

**5. News and Recent Issues:**

* **Recent Earnings Announcement (July 25, 2024):** ABBV reported strong Q2 2024 earnings, beating analysts' estimates. The company highlighted the continued success of its key drugs like Humira and reported solid revenue growth.
* **Market Outlook:** The recent earnings beat has generated positive sentiment around ABBV. Analysts are generally optimistic about the company's future prospects, given its strong pipeline and diversified product portfolio.
* **Analyst Opinions:** Several analysts have recently upgraded their ratings on ABBV, citing the strong earnings performance and favorable long-term outlook.
* **Performance Highlights:** ABBV's stock price has been relatively stable in recent months, despite some downward pressure. The company's strong financial performance and positive industry outlook suggest potential for continued growth in the future.

**6. Overall Analysis:**

ABBV's strong financial performance, coupled with a positive outlook and favorable analyst sentiment, makes it a potentially attractive investment. The stock's recent downward movement, however, could offer a buying opportunity for investors seeking long-term value. It's worth noting that while ABBV has outperformed the S&P 500 in the past, its recent price action and technical indicators suggest caution.  

**7.  Recommendation:**

Based on the current analysis, ABBV appears to be a solid long-term investment opportunity. While the stock has experienced some recent volatility, its strong earnings performance, positive market outlook, and above-average expected return make it a promising addition to any diversified portfolio. Investors should closely monitor the stock's price action and technical indicators to determine the best entry point.  
